Henry Nasrallah, MD

ADVANCE: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Negative Symptoms of Schizophrenia

Pimavanserin is a selective, 5-hydroxytryptamine (5-HT)2A receptor inverse agonist/antagonist with lower activity at 5-HT2C receptors. Previous studies have shown beneficial effects of ad...

Dragana Bugarski-Kirola , MD, MBA, MSc;

Srdjan Stankovic , MD, MSPH;

Celso Arango , MD, PhD;

Henry Nasrallah , MD;

I-Yuan Liu , MSc;

Brandon Abbs , PhD;

Maurizio Fava , MD, PhD;

10/08/2020

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8

November 8 ⁠–⁠ November 10

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Henry Nasrallah, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products